McLaren Alistair, Cartwright Douglas, Ross Ewen, Roxburgh Patricia
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
J Immunother Precis Oncol. 2021 Apr 15;4(3):171-174. doi: 10.36401/JIPO-20-33. eCollection 2021 Aug.
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) 1 and 2, has been shown to improve progression free survival in patients when used as maintenance treatment after first-line platinum-based chemotherapy in advanced stage (III to IV) high-grade ovarian cancer, and after platinum-based chemotherapy for relapsed disease. For grades greater than III, commonly reported side effects include bone marrow suppression (thrombocytopenia, neutropenia, and anemia) and hypertension. However, grade ≥ III pneumonitis was not reported in phase III trials (PRIMA or NOVA). We present a case of life-threatening niraparib-induced pneumonitis. With recent approval for use of first-line maintenance niraparib in the United States and Europe, knowledge of the side effects and how to manage them is vital.
尼拉帕利是聚（腺苷二磷酸[ADP] - 核糖）1和2的抑制剂，已显示出在晚期（III至IV期）高级别卵巢癌一线铂类化疗后用作维持治疗时，以及在铂类化疗后用于复发性疾病时，可改善患者的无进展生存期。对于大于III级的情况，常见的副作用包括骨髓抑制（血小板减少、中性粒细胞减少和贫血）和高血压。然而，III期试验（PRIMA或NOVA）中未报告≥III级肺炎。我们报告一例危及生命的尼拉帕利诱发的肺炎病例。随着尼拉帕利在美国和欧洲最近获批用于一线维持治疗，了解其副作用及如何处理至关重要。
